 | Erectile Dysfunction Market Assessment and Analysis 2007 to 2022
The market for Erectile Dysfunction (ED) drugs is growing fast with a CAGR of 4.9% for the period 2006-2012. The ED market contains three leading drugs Viagra, Levitra and Cialis. Viagra, already a blockbuster drug, is the most popular and recognised brand on the market. Furthermore, high revenues are predicted by visiongain for the top three ED drugs, with Cialis reaching blockbuster status by 2007. This detailed report also highlights pipeline developments and important contemporary issues, especially commercial drivers and restraints. The purpose of this market analysis by visiongain is to examine prospects for Erectile Dysfunction (ED) drugs from 2007-2022, including sales forecasts for leading pharmaceutical products.Most men experience ED at some points in their lives usually by the age of 40, but are not necessarily psychologically affected by it. Some men, however, experience chronic and complete ED. Over 150 million men worldwide are unable to achieve and maintain an erection adequate for satisfactory sexual intercourse; visiongain expects this figure to double by 2020. Despite its commonplace occurrence, ED is a notoriously under-reported, under-recognised, and an under-treated chronic illness. It is estimated that 85% to 90% of all ED goes undiagnosed.The ED Market Report examines the market critically through a comprehensive review of available information. Sources include industrial databases, commercial news, published reports, economic research and consultation with experts. Visiongain applies financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion. In particular, The ED Market concentrates on the following essential aspects of the market:> Discussion of the current pharmaceutical market> Forecast of the worldwide pharmaceutical market from 2007-2012> Drivers and restraints facing the ED market> Opportunities and threats facing the ED market> Growth of the ED drugs market between 2007-2012 > Commercial prospects for the market-leading drugs, with sales forecasts from 2007-2012> The potential of generics manufacturers to penetrate this market> Pipeline developments with blockbuster potential> Currently marketed drugs with blockbuster potential> Discussion of unmet therapeutic needs and relative advantages of productsWhy you should buy this report: > To receive a comprehensive analysis of the prospects for ED drugs from 2007-2012> To discover predicted revenues, growth rates and other key metrics for leading pharmaceutical treatments from 2007-2012> To determine key activities of leading companies> To discover "hot" pipeline developments and up-and-coming products> To determine the forces that influence the market for ED products:> Competitive characteristics of the market> Drivers > Restraints> Strengths, weaknesses, opportunities and threats (SWOT analysis)> To find out where the ED market is heading - both technologically and commercially Why You Must Buy This Report:This report features tables, graphs and charts, news, insights, the past and present developments in the ED Market. Amongst the catalogue of products in the ED pipeline is transdermal therapies. Neew innovative products for ED has generated a high level of interest from; top-tier companies, the major players in the ED circle and niche companies alike.This visiongain report is the single tool to equip you with the latest trends in all regional markets and why drug companies are aiming for a new generation of drugs. Visiongain recommends this astute report to the major players in the field as it will arm you with the clinical challenges that larger companies face to date, thus the rising inherent cost of R&D expenditure to in order meet the requirements set by major regulatory authorities for larger evidence of clinical data before any authorisation. The ED Market Assessment & Analysis 2007-2022 report is a must buy, because it presents in-depth and unbiased financial analysis for the near-term, medium-term and the long-term, market dynamics. Unique benefits to you when you order this report:- Primary research throughout. You will not find this information anywhere else- Report stored in your reading room for ever- Full searchable report when you buy the company or corporate editions- Copies can be printed off for offline reading- Packed with charts, analysis, figures, graphs and tables- PRICING - - Single use licence $2,995.00- Departmental copies (this entitles up to 5 individual users in your department) of this report are available for only USD $5,995.00. This is not suitable for library usage. - Allow your whole company to have access to this information for only USD $9,995.00. Company-wide License allows your whole company access and intranet use on CD Rom and .pdf. Suitable for library storage and use.- Does your company have over 2,500 employees? Have the whole company access this information for a special rate of only USD $13,995.00January 2008 Pages 89
Table of Contents
License
|
|
|
|
